Eventide Funds are a product of   Eventide Asset Management   Leaving Eventide Product Page

Ticker

ETILX

$53.95 ▲ 1.81% 11/21/2024

Nav

$53.95 ▲ 1.81% 11/21/2024

About the Fund

  • Diversified, equity mutual fund representing our “best ideas”
  • Seeks long-term capital appreciation
  • Historical emphases in Healthcare and IT

Annualized Returns

1-Year11.26%
5-Year9.18%
10-Year10.37%
Since Inception13.12%

Morningstar

★★★

US Fund Mid-Cap Growth

Fact Sheet Prospectus

Morningstar overall star rating is as of 09/30/2024 for the Fund's Class I shares compared to 511 funds in the US Fund Mid-Cap Growth category. The overall ranking is derived from a weighted average of performance associated with its 3-year, 5-year and 10-year (where applicable) Morningstar Rating metrics. The Morningstar globe ranking is as of 08/31/2024 compared to the sustainability ratings of 1595 funds in its category. Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Fund expenses: Class I, Gross Expenses 1.18%, Net Expenses 1.18%.

  • Overview

    Overview

    Fund Objective

    Seeks to provide long-term capital appreciation.

    About the Fund

    A diversified mutual fund representing our "best ideas" for long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.

    Fund Distinctives

    A Thematic Approach
    Seeking to invest in companies best positioned to participate in long-term secular investment themes.

    Creating Compelling Value for Society and the Global Common Good
    Focused on identifying and investing in companies capable of increasing profitability and growth by serving well the needs of customers, employees, suppliers, communities, the environment, and society broadly.

    Designed as a Non-Correlated Source of Return
    Portfolio is constructed with goals of high internal diversification and low market correlation.

    There is no guarantee that the Adviser’s approach will produce the desired results. All investments involve risk, including the possible loss of principal. Portfolio Composition is subject to change at any time, and should not be considered investment advice.

  • Performance and Risk

    Trailing Returns (%) As of the quarter ending 09/30/2024

    Eventide Gilead Fund
    As of 11/21/2024.

    YTD    		3-month1-year3-year5-year10-yearSince InceptionInception Date
    Class I3.31%4.5611.26-6.019.1810.3713.1202/02/2010
    Class A without load3.09%4.5010.98-6.248.9110.1113.9410/28/2009
    Class A with 5.75% load-2.84%-1.524.59-8.077.639.4613.4910/28/2009
    Class C2.39%4.2910.15-6.948.099.2813.0710/28/2009
    Class N3.13%4.5111.03-6.208.9610.1512.6107/08/2008
    Benchmarks        
    Bloomberg US Mid Cap Growth Index22.05%8.0927.453.3411.8411.0810.6107/08/2008
    Russell Midcap Growth Index27.41%6.5429.332.3211.4811.3011.0007/08/2008


    Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. This material must be read along with the Fund's prospectus, which may be obtained at eventidefunds.com/prospectus. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).

    Market Risk AS OF 09/30/2024

    Standard DeviationBetaAlpha(%)R-Squared(%)
    3-yrInception3-yrInception3-yrInception3-yrInception
    Eventide Gilead I21.3219.800.981.09-9.25-0.1689.5286.35
    Bloomberg US Mid Cap Growth Index20.5516.961.001.00--100.00100.00
    Russell Midcap Growth Index21.3117.321.021.01-0.870.0397.1398.06
  • Portfolio
  • Investment Team
    image of Finny Kuruvilla

    Finny Kuruvilla, MD, PhD  serves as Co-Chief Investment Officer and Senior Portfolio Manager for Eventide. He serves as the Lead Portfolio Manager for the Eventide Gilead Fund, the Eventide Healthcare & Life Sciences Fund, and the Eventide Exponential Technologies Fund. He also is a Managing Director for Eventide Ventures, as well as a Founding Member of Eventide. Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital, where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, an SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.

  • Literature

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads, intense competition, and sensitivity to economic cycles. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.

This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at https://www.eventidefunds.com/prospectus or by calling 1-877-771-EVEN (3836). Investors should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.

Eventide 1130-1521 - 11/22/2024 09:29am